Post-Seed Venture Capital: What Is It? Is it Right for Me?
January 8, 2020 @ 5:00 pm - 8:30 pm
Startups: If you’re committed to your business vision, then you MUST start planning for venture financing.
Even if your startup is brand-new, NOW is the time to map out your complete business growth path — all the way to venture financing.
Get a crystal-clear picture of the process as we welcome three noted life science business financing experts to our Lowell center after work on Wednesday, January 8.
Join us and:
Understand how venture financing works today.
Learn what to look for (and look OUT for) in a VC offer.
Learn how to prepare your full business financing plan—from angel investors to VCs.
Find out the preparations you need to make to advance to each stage of financing.
Get expert answers to all your business financing questions.
Network with VCs, other investors, and your entrepreneur peers.
Enjoy complimentary snacks and beverages.
PLUS, practice and improve your pitch!
Come with your pitch deck, because you can enter your name to give your business presentation and get valuable feedback from our panel.
5:00 – Registration & Networking w/ food & drink
5:30 – Fireside Chat with Bill Yelle, Nancy Briefs, and moderator Vinit Nijhawan.
6:30 – Q&A and Networking
Online tickets: $10.00
*This event will also include a 200k Challenge 2020 Info Session*
*Free parking included*
Meet the Panel:
Vinit Nijhawan is Interim Executive Director at Massachusetts Technology Transfer Center in UMass President’s Office. Vinit was Managing Director at UnitedLex focused on academic IP commercialization. Vinit was Managing Director, Office of Technology Development at Boston University where he launched 8 venture-backed spinoffs and successfully executed a patent monetization program. Vinit teaches MBA courses on Entrepreneurship at BU Questrom School of Business, over 450 students have taken his courses. Vinit has over 30 years experience building five startups: as CEO of three, five were acquired. Vinit was Venture Partner at Key Venture Partners and his one investment was acquired for $430M. Vinit is an advisor and board member to several technology startups and was a Mass High Tech All-Star in 2005. Vinit has participated in over 240 panel discussions and paper presentations, and was a Board Member of Mass Ventures, an early stage, quasi-public Massachusetts venture capital firm, a co-founder of EdTech Accelerator/Incubator LearnLaunch, ex-President of Massachusetts Association of Technology Transfer Offices and co-founder of Waterloo Alumni Angels. Vinit is also serving or has served on non-profit boards of VentureCafe Foundation, National Academy of Inventors, TiE Global. Vinit earned a B.A.Sc in electrical engineering from the University of Waterloo in Ontario, Canada.
Nancy Briefs‘ background includes 35+ years in the medical device industry. She is a serial entrepreneur and has been an integral team member responsible for successfully developing and commercializing innovative paradigm-shifting technologies with six (6) prior MedTech startups. Having raised over $500M in capital and six successful liquidity events (including an IPO with Goldman) she has proven the ability to lead teams from concept thru commercialization and value creation. She has served on the Boards of: HealthHelm, Digital Cognition Technologies, InfoBionic, MyndBlu, CardiAQ Valve Technologies, MDMA (Medical Device and Manufacturers Association), Apama Medical, Direct Flow Medical, Eleme Medical, and Percardia.
An entrepreneur inventor she is listed on seven issued and two pending US patents.
Nancy has an MBA in Marketing and Finance from Golden Gate University and a BA and BSB from Emporia University.
William E. Yelle
Executive Chairman, Envisia Therapeutics
Bill has spent over 30 years in the biopharmaceutical industry, with experience ranging from large pharma to early stage, venture-backed companies. He currently serves as Executive Chairman of Envisia Therapeutics, as well as an advisor to several entrepreneurial startups. He is also an adjunct faculty member at the Manning School of Business.
Prior to Envisia, Bill served as CEO of Aldea Pharmaceuticals, where he built an executive team, completed a successful $28 M Series B raise and brought two programs into the clinic. Prior to Aldea, he was Senior Vice President of Corporate Development and Licensing for Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.). While at Sepracor, Bill was instrumental in the companies’ transition from an early stage clinical organization with just over 30 employees into a fully integrated pharmaceutical company consisting of close to 3,000. At Sepracor, he was responsible for the consummation of over 30 material transactions, the most notable being the company’s sale to Dainippon Sumitomo Pharma for $2.6 billion in 2009. Prior to joining Sepracor in 1995, Bill held various positions of increasing responsibility in Pfizer’s U.S, Pharmaceuticals Group.
In addition to working as Executive Chair at Envisia, Bill has served on the boards of LQ3 Pharma and Aldea Pharmaceuticals.
Bill has an M.B.A. in Management/Marketing from Columbia University, a M.S. in Organic Chemistry from the University of California at Berkeley and a B.S. Cum Laude from the University of Massachusetts Lowell.
Maria Berkman, MD, MBA,
Director, and Head of the MedTech practice, Broadview Ventures.
Maria shares responsibility for all aspects of Broadview’s investment activity, from identification and screening of new opportunities, through due diligence, negotiation of deal structure, and portfolio company board involvement.
Prior to joining Broadview Ventures, Maria was a management consultant at Monitor Group, where she specialized in life sciences with a focus on corporate, franchise, and asset-level commercialization strategy and competitive strategic planning for both BioPharma and MedTech clients. Prior to joining Monitor Group, Maria trained within the Partners HealthCare System at Newton Wellesley Hospital in General Surgery. Maria earned an MD from the UCLA School of Medicine, graduating Alpha Omega Alpha with a research focus in cardiothoracic and trauma surgery, and earned an MBA from the Anderson School of Management at UCLA.
Maria serves on the boards of Adient, Aria CV, AtaCor, FineHeart, Vascular Graft Solutions and Vectorious, and previously served on the boards of Apama (acquired by Boston Scientific) and Capricor (NASD:CAPR).
In addition to her role at Broadview Ventures, Maria contributes time as a SBIR/STTR grant reviewer for the National Science Foundation and is a Strategic Advisory Board Member for the RAD BioMed Accelerator in Tel Aviv, Israel.
Want to submit your own event? Create an account here